Denali Therapeutics Inc. (DNLI) Form 8-K — Jun 18, 2026
$DNLIForm 8-KItems 1.01, 7.01, 9.01Filed Jun 18, 2026, 8:01 AM ET0001714899-26-000081Original filing
Denali Therapeutics entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in cash. The voucher was awarded by the FDA following the March 2026 accelerated approval of AVLAYAH for the treatment of Hunter syndrome.
Key figures
- Deal Value Usd
- 195000000
Price after filing
1 day: 0.0%7 days: +6.1%30 days: -2.5%
Close on the filing date to close N calendar days later (from $23.31). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.